Cover Image
市場調查報告書

Xarelto(心房纖維顫動治療藥物):開發平台分析及市場預測

Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 244301
出版日期 內容資訊 英文 91 Pages
訂單完成後即時交付
價格
Back to Top
Xarelto(心房纖維顫動治療藥物):開發平台分析及市場預測 Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
出版日期: 2014年07月31日 內容資訊: 英文 91 Pages
簡介

本報告提供心房纖維顫動治療藥物 Xarelto 的開發平台評估及市場預測,以市場特徵為首,評估分析競爭,開發平台等,加進未來市場競爭預測,為您概述為以下內容。

1目錄

  • 1.1 表格一覽
  • 1.2 圖表一覽

2 簡介

  • 2.1 心房纖維顫動市場
  • 2.2 流行病學
  • 2.3 病因論及危險因素
    • 2.3.1 AF相關症狀
  • 2.4 GlobalData 分析及預測報告指南

3 心房纖維顫動: 市場特性

  • 3.1 心房纖維顫動市場
  • 3.2 心房纖維顫動 市場預測 及 年複合成長率
  • 3.3 心房纖維顫動推動市場成長要素
    • 3.3.1 未滿足需求高
    • 3.3.2 強力開發平台
    • 3.3.3 罹患率的增加及老年人口
    • 3.3.4 宣導活動的組織化
  • 3.4 心房纖維顫動市場上的障礙
    • 3.4.1 確立的治療的限制
    • 3.4.2 出現的治療方法的高成本

4 心房纖維顫動的分類:簡介

  • 4.1 AF 分類
    • 4.1.1 AF的病理學
    • 4.1.2 心房纖維顫動的診斷
    • 4.1.3 心房纖維顫動的衝擊

5 心房纖維顫動的治療方法可供選擇的方案及管理

  • 5.1 心跳數控制及心律控制
  • 5.2 心跳數控制V.S.心律控制

6 Xarelto

  • 6.1 簡介
  • 6.2 作用機制
  • 6.3 臨床研究
  • 6.4 Xarelto 核準情況
  • 6.5 Xarelto 影響其銷售量的因素
    • 6.5.1 不亞於抗凝血劑
    • 6.5.2 投藥預定的便利性
    • 6.5.3 Xarelto 反彈效果的影響
  • 6.6 藥物評估
    • 6.6.1 藥物風險·效益評估
    • 6.6.2 競爭的強度
  • 6.7 銷售預測
    • 6.7.1 Xarelto 目標患者群
    • 6.7.2 投藥
    • 6.7.3 市場普及率
    • 6.7.4 治療的年度成本
    • 6.7.5 Xarelto 的全球市場銷售額預測

7 附錄

  • 7.1 市場定義
  • 7.2 簡稱
  • 7.3 研究調查方法
    • 7.3.1 調查範圍
    • 7.3.2 二級研究
    • 7.3.3 預測
    • 7.3.4 核可服用的患者數
    • 7.3.5 藥物的純普及率
    • 7.3.6 年度淨用藥量
    • 7.3.7 治療的年度成本
  • 7.4 藥物銷售額預期模式
  • 7.5 諮詢方式
  • 7.6 免責聲明
  • 7.7 資訊來源

表格一覽

1.1 表格一覽

  • 表格1:心房纖維顫動的流行病學
  • 表格2:風險要素眼前的AF危險度增加
  • 表格3:心房纖維顫動所有危險因子階層化
  • 表格4:心房纖維顫動分類
  • 表格5:心房纖維顫動管理治療指南
  • 表格6: Xarelto 、第三階段臨床實驗結果
  • 表格7: Xarelto 核準情況
  • 表格8: Xarelto 藥物風險·效益評估
  • 表格9: Xarelto 、心房纖維顫動,療法的全球市場,年度的成本($)
  • 表格10: Xarelto 、心房纖維顫動,全球市場,銷售額預期(m美元),預測
  • 表格11: Xarelto 、心房纖維顫動,美國,銷售額預期(m美元),預測
  • 表格12: Xarelto 、心房纖維顫動,英國,銷售額預期(m美元),預測
  • 表格13: Xarelto 、心房纖維顫動,法國,銷售額預期(m美元),預測
  • 表格14: Xarelto 、心房纖維顫動,德國,銷售額預期(m美元),預測
  • 表格15: Xarelto 、心房纖維顫動,義大利,銷售額預期(m美元),預測
  • 表格16: Xarelto 、心房纖維顫動,西班牙,銷售額預期(m美元),預測
  • 表格17: Xarelto 、日本的心房纖維顫動,銷售額預期(m美元),預測

圖表一覽

  • 圖1:心房纖維顫動,全球市場,市場規模預測(10億美元),預測
  • 圖2:心房纖維顫動-分子的比例(各開發階段)
  • 圖3:心房纖維顫動的得病率族群的增加
  • 圖4:標準心律V.S.心房纖維顫動
  • 圖5: 心房纖維顫動 模式的寬廣的分類
  • 圖6: 心房纖維顫動相關病徵,各比例
  • 圖7:心房纖維顫動的患者的治療用的目標(AF)
  • 圖8:新發現的心房纖維顫動(AF)的管理
  • 圖9: Xarelto 藥物模式圖
  • 圖10: Xarelto 、心房纖維顫動,全球市場,銷售額預期(m美元),預測
  • 圖11: Xarelto 、心房纖維顫動,美國,銷售額預期(m美元),預測
  • 圖12: Xarelto 、心房纖維顫動,英國,銷售額預期(m美元),預測
  • 圖13: Xarelto 、心房纖維顫動,法國,銷售額預期(m美元),預測
  • 圖14: Xarelto 、心房纖維顫動,德國,銷售額預期(m美元),預測
  • 圖15: Xarelto 、心房纖維顫動,義大利,銷售額預期(m美元),預測
  • 圖16: Xarelto 、心房纖維顫動,西班牙,銷售額預期(m美元),預測
  • 圖17: Xarelto 、日本的心房纖維顫動,銷售額預期(m美元),預測
  • 圖18: Xarelto 、心房纖維顫動,全球市場,各國銷售額分佈,預測
  • 圖19:核准服用藥物的患者人數

  • 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

    目錄

    GlobalData has released its new PharmaPoint Drug Evaluation report, "Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023". The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

    Xarelto was approved in the EU for the prevention of non-valvular atrial fibrillation (AF)-related stroke and systemic embolism, and for the treatment of deep vein thrombosis (DVT). On July 1, 2011, Xarelto was approved in the US to reduce the risk of blood clots, DVT, and pulmonary embolism (PE) following hip or knee replacement surgery, and in November of the same year, it was approved for stroke prevention in patients with non-valvular AF.

    Scope

    • Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
    • Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
    • Sales forecast for Aricept for the top seven countries from 2013 to 2023.
    • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

    Reasons to buy

    • Understand and capitalize by identifying products that are most likely to ensure a robust return
    • Stay ahead of the competition by understanding the changing competitive landscape for ACS
    • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
    • Make more informed business decisions from insightful and in-depth analysis of Aricept performance
    • Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

    Table of Contents

    1. Table of Contents

    • 1.1. List of Tables
    • 1.2. List of Figures

    2. Introduction

    • 2.1. Catalyst
    • 2.2. Related Reports
    • 2.3. Upcoming Related Reports

    3. Disease Overview

    • 3.1. Etiology and Pathophysiology
      • 3.1.1. Etiology
      • 3.1.2. Pathophysiology
      • 3.1.3. Prognosis
      • 3.1.4. Quality of Life
    • 3.2. Symptoms

    4. Disease Management

    • 4.1. Treatment Overview

    5. Competitive Assessment

    • 5.1. Overview
    • 5.2. Strategic Competitor Assessment

    6. Unmet Need and Opportunity

    • 6.1. Overview
    • 6.2. Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques
      • 6.2.1. Unmet Need
      • 6.2.2. Gap Analysis
      • 6.2.3. Opportunity
    • 6.3. Therapies that Treat Fibrotic Myocardium and Associated Comorbidities
      • 6.3.1. Unmet Need
      • 6.3.2. Gap Analysis
      • 6.3.3. Opportunity
    • 6.4. LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients
      • 6.4.1. Unmet Need
      • 6.4.2. Gap Analysis
      • 6.4.3. Opportunity
    • 6.5. Antidotes for New Oral Anticoagulants (NOACs)
      • 6.5.1. Unmet Need
      • 6.5.2. Gap Analysis
      • 6.5.3. Opportunity
    • 6.6. Blood-Thinning Agents with Significantly Reduced Bleeding Risks
      • 6.6.1. Unmet Need
      • 6.6.2. Gap Analysis
      • 6.6.3. Opportunity

    7. Pipeline Assessment

    • 7.1. Overview
    • 7.2. Clinical Trials by Phase and Trial Status
    • 7.3. Promising Drugs in Clinical Development

    8. Xarelto (rivaroxaban)

    • 8.1. Overview
    • 8.2. Efficacy
    • 8.3. Safety
    • 8.4. Dosing and Formulation
    • 8.5. Potential Clinical Positioning
    • 8.6. Potential Commercial Positioning
    • 8.7. Pricing and Reimbursement

    8.8. SWOT Analysis

    • 8.9. Forecast

    9. Appendix

    • 9.1. Bibliography
    • 9.2. Abbreviations
    • 9.3. Methodology
    • 9.4. Forecasting Methodology
      • 9.4.1. Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population
      • 9.4.2. Diagnosed Acute Coronary Syndrome Patients
      • 9.4.3. Percent Drug-Treated Patients
      • 9.4.4. General Pricing Assumptions
      • 9.4.5. Generic Erosion
      • 9.4.6. Pricing of Pipeline Agents
    • 9.5. Physicians and Specialists Included in this Study
    • 9.6. About the Authors
      • 9.6.1. Author
      • 9.6.2. Reviewer
      • 9.6.3. Global Head of Healthcare
    • 9.7. About GlobalData
    • 9.8. Disclaimer

    List of Tables

    • Table 1: Antiplatelet Agents that Inhibit Platelet Activation
    • Table 2: Anticoagulants that Inhibit the Coagulatory Cascade
    • Table 3: Symptoms of Acute Coronary Syndrome
    • Table 4: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI)
    • Table 5: Most Prescribed Drugs for ACS by Class in the Global Markets, 2014
    • Table 6: Leading Treatments for Acute Coronary Syndrome, 2014
    • Table 7: Unmet Need and Opportunity in Acute Coronary Syndrome
    • Table 8: Acute Coronary Syndrome - Clinical Trials by Phase and Status, 2014
    • Table 9: Acute Coronary Syndrome - Late-Stage Pipeline, 2014
    • Table 10: Comparison of Therapeutic Classes in Development for ACS, 2014
    • Table 11: Product Profile - Xarelto (rivaroxaban)
    • Table 12: Xarelto (rivaroxaban) SWOT Analysis, 2014
    • Table 13: Global Sales Forecasts ($m) for Xarelto, 2013-2023
    • Table 14: Price Sources and Calculations, by Country
    • Table 15: Physicians Surveyed, By Country

    List of Figures

    • Figure 1: The ACS Timeline and the Scope of GlobalData's ACS Report and Forecast
    • Figure 2: Progression of Coronary Artery Disease, Atherosclerotic Plaque Rupture, Thrombosis, and Acute Coronary Syndrome
    • Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis
    • Figure 4: Electrocardiography in the Diagnosis of ACS
    • Figure 5: Acute Coronary Syndrome Therapeutics - Clinical Trials by Phase in the 7MM, 2014
    • Figure 6: Competitive Assessment of Late-Stage Pipeline Agents for ACS, 2013-2023
    Back to Top